FDA Registrations
The innovative Merilas product family, developed by Meridian AG for the treatment of retinal disorders and Glaucoma, has successfully obtained approval from the United States Food and Drug Administration (FDA) as of September 12, 2023.
Additionally, the MR Q series has been cleared by the FDA on January 25, 2024.
The FDA approval of this products is an important milestone for the Meridian Group and reflects our commitment to providing high quality and inventive healthcare solutions that meet the diverse needs of patients and physicians around the world.
This certification from the FDA confirms that our products are based on advanced technology and underwent rigorous testing proving their safety and efficacy.